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Abstract: Corticosteroids, widely used in the
treatment of collagen tissue diseases, increase
the number of neutrophils and decrease the
total numbers of lymphocytes, monocytes,
eosinophils and basophils. In addition,
corticosteroids alter important functional
activities of both lymphocytes and monocytes.
They suppress the bactericidial activities of
phagocytes. In this manner, the resistance to
infections is reduced. Cytotoxic drugs can
have profound effects on the production and
function of both phagocyte cells and
lymphocytes.
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We followed up 115 patients with collagen
tissue disease for two years and 22 of them
had infections. Eight of these 22 patients had
urinary tract infection, six had lung infection,
four had upper respiratory tract infections,
two had wound infections, and one had
intestinal infestation. All of the patients were

Introduction
The most important function of the immune system is
to protect the host against harmful microorganisms.
Defense mechanisms include the physical barriers of the
skin and mucosal membranes, the complement system,
prostaglandins, cytokines, lysozymes, natural killer (NK)
cells and phagocytic cells. The iatrogenic destruction of
anatomical barriers causes many bacterial and fungal
infection agents to enter the host. Immunosuppressive
agents used in collagen tissue diseases can lead mucositis
and sometimes to cystitis (1).
Phagocytic cells (e.g. neutrophils, macrophages) have
a very important function in the phagocytosis of immune
complexes and infectious agents. When infectious agents
pass the primary barriers, polymorphonuclear leucocytes
provide immunity against potential pathogens such as
gram (+) and gram (-) bacteria and fungal agents. Monocytes and macrophages in the reticuloendothelial system

treated with appropriate antimicrobial agents
but two patients died due to septicemia.
Infection remains a significant cause of
morbidity and mortality in patients with
collagen tissue diseases. Consequently, the
early diagnosis and treatment of infections are
very important for the successful medical
management of these patients. The intensity
of immunosuppressive therapy is the
dominant risk factor for infection in these
patient
populations.
Because
the
manifestations of infection in patients with
collagen tissue diseases are highly variable,
the clinician must always be alert to the
possibility of infection even if the clinical
presentation is highly suggestive of an
exacerbation of the underlying disease.
Key Words: Collagen tissue diseases,
Infection, Corticosteroid, Cytotoxic drugs.

provide an important support for the elimination of viruses, mycobacteria, and certain viruses that neutrophils do
not affect (2).
Neutropenia is the most serious problem in collagen
tissue diseases. Neutropenia is generally associated with
immunosuppressive therapy. Sepsis risk increases when
the neutrophil count falls below 500/mm3 and remains in
this state for 20 days. The immunological response of
the host to the microorganisms occurs by means of
immunoglobulins and T lympocytes. The antibody-bacteria complexes are cleaned either by phagocytes or by
macrophages in the reticuloendothelial system (1).
The complement system is a potent biological system
in the host defense. Among the biological effects of complements are chemotaxis and anaphylaxis, opsonization
and phagocytosis of microorganisms, the clearance of
immune complexes from circulation and an increase in
vascular permeability (3).
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Infection is of special significance in collagen tissue
diseases. Patients with collagen tissue disease become
sensitive to infections because of the use of corticosteroids and/or immunosuppressive drugs in the treatment. Corticosteroids inhibit neutrophils from migrating
to the inflammation site, from adhering to the vasculary
endothelium and from exerting bactericidal effects. Using
a high dose steroid can inhibit the production of
immunoglobulins (4). It can also cause
lymphocyte,
monocyte, eosinophil and basophil counts to decrease. In
addition, it suppresses the antibacterial activities of
phagocytes. It causes the lymphoid subpopulation to
decrease, especially in T lymphocyte counts. Its effect on
B lymphocytes is less than that on T cells. The administration of a high dose corticosteroid decreases the production of Ig G and Ig A.
Cytotoxic drugs cause neutropenia and affect the
counts of T and B lymphocytes. Cyclophosphamide, which
is a potent immunosuppressive drug, influences primarily
the B lymphocytes. However, although it influences all
cells in bone marrow, it does not often cause leukopenia
(5). Azathiopyrine decreases both T and B lymphocytes in
long term administration. It suppresses the synthesis of
immunoglobulins. It does not influence the neutrophil
function. It can cause bone marrow suppression (4).
Methotraxate has an evident immunosuppressive effect.
Table 1.

It suppresses the synthesis of antibodies and the primary
and secondary immune response (6). The predominant
immunological defects and the pathogen microorganisms
caused by drugs administered in the treatment of collagen
tissue diseases are shown in Table 1.
As mentioned above, the risk of infection increases
in patients with collagen tissue diseases. This situation is
important because of the activation of diseases. In this
article, we discuss the cause and results of infection in collagen tissue disease in the light of the literature.

Materials and Methods
This study included 115 patients with collagen tissue
disease who were followed up between 1996 and 1998.
Infection was detected in 22 (19%) of these patients
during the follow-up period. The average age of the
patients was 43 (18-65). Twelve of the patients with
infection had SLE, eight had RA, and two had MCTD. For
the patients with flares in clinical findings and symptoms,
throat, urinary and blood cultures, as well as sputum cultures (if the patient expectorated sputum) were performed.
The patients were treated in accordance with the
results of the cultures and antibiograms. In addition, the

Evident immunological defects and pathogens associated with certain drugs being administered in the treatment of collagen tissue diseases.

Abnormality

Drugs

Bacteria

Fungus

Qualitative defect
of phagocytic
function or
neutropenia

CS
CYC
AZT

Gram (+)
Gram (-)
bacteria

Candida
Aspergillus

Defective
cell-mediated
immunity

CS
CYC
AZT
MTX
CY-A

Mycobacteries
Listeria
Salmonella
Nocardia

Histoplasmosis
Coccidioides
Cryptococcus

Defective
humoral
immunity

CYC
CS
AZT

S. Pneumonia
H. Influenzae

CMV: Cytomegalovirus
CS: Corticosteroid
MTX: Methotraxate
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EBV: Ebstaine-Barr virus
AZT: Azathioprine
CY-A: Cyclospor›ne –A

VZV: Varicella-Zoster Virus
CYC: Cyclophosphamide
P.C: Pneumocystis Carinii

Protozoa

Virus

P.C.
Toxo
Strong.
stercoralis

CMV
EBV
VZV
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treatment of the underlying disease was continued. All
the patients with SLE in whom infection developed were
administered corticosteroid. While the patients with RA
were administered methotraxate, sulfasalazin and nonsteroid antiinflamatory drugs, those with MCTD were
administered corticosteroid and nonsteroid antiinflamatory drugs.

Results
In four of the patients with SLE in whom infection
was detected, more than one infection occurred and there

Table 2.

was infection in only one site in eight patients developing
infection. In two of the patients with RA, infection developed in more than one site while in six of them infection
developed in only one site. There was infection in only
one site in patients with MCTD. Infection was detected
mostly in the urinary system, followed by lung infection
and upper respiratory infection. Sepsis was detected in
eight patients. Improvements were seen in clinical findings and symptoms in other patients after treatment of
the infection. The distribution of patients, agents of
infections, and infection sites of patients with collagen tissue disease developing infection are shown in Table 2.

Agents associated with infection and sites in collagen tissue diseases.

PATIENT

SEX

AGE

DIAGNOSIS

1

F

33

RA

2
3
4
5
6
7
8

F
F
F
M
F
F
F

38
58
57
69
60
30
61

RA
RA
RA
RA
SLE
SLE
RA

9

F

30

SLE

10
11
12
13
14

F
F
F
F
F

55
21
67
42
18

SLE
SLE
RA
SLE
SLE

15
16

F
F

21
20

MCTD
SLE

17

M

33

MCTD

18

F

35

SLE

19
20
21
22

F
M
M
F

23
43
67
49

SLE
SLE
RA
SLE

INFECTION SITE

AGENT

Throat
Blood
Vagina
Lung
Lung
Urinary system
Urinary system
Colon
Lung
Blood

S. epidermidis
S. epidermidis
C. albicans
S. aureus
S. pneumonia
S. aureus
E. coli
E. histolytica
S. pneumonia
C. albicans
E. coli
C. albicans
E. coli
S. aureus
S. aureus
E. coli
E. coli
Proteus spp.
P. aeruginosa
C. albicans
S. epidermidis
Klebsiella
S. aureus
S. aureus
S. aureus
S. aureus
Pseudomonas spp.
S. epidermidis
E. coli
E. coli+Klebsiella
S. pneumonia
S. aureus

Throat
Urinary
Blood
Joint
Urinary
Urinary
Blood
Lung
Throat
Blood
Urinary
Joint
Blood
Joint
Blood
Lung
Blood
Urinary
Urinary
Lung
Urinary

system

system
system

system

system
system
system
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Discussion
Corticosteriods and immunosuppresive drugs are of
indispensable importance in the treatment of collagen tissue diseases. Before the use of these drugs, there were
high levels of morbidity and mortality. Notable decreases
have been achieved with these drugs. Although these
drugs have many beneficial effects, they also have unignorable degrees of side effects, of which infection is significant. The development of infection in these patients is
a triggering factor in the exacerbation of the disease.
Infection is also a major cause of morbidity in patients
with collagen tissue diseases (7-9).
Bradley et al. (10) investigated the risks of infection
in patients with vasculitis who were being administered
cyclophosphamide. The total follow- up time of the
patients was 201 months and 17 infections were detected during this period. They detected 5 lung infections, 4
skin infections, and 3 urinary tract infections. The other
infection sites detected were the peritoneum, gastrointestinal system, blood, paranasal sinus, knee and bursa of
olecranon. In this study, the infectious agents were gram
(+) and (-) bacteria, anaerobic bacteria, candida, P. Carinii
and herpes. However, the most common agents were
enterobacteria, pseudomonas and staphylococcus. Many
agents were detected in 4 patients. Two patients died
during follow up because of pneumonia.
Duffy et al. (11) followed up 81 patients with SLE for
5 years. During this time they detected 53 incidents of
infection, 34 of which were serious. The serious infections were pneumonia, bacteriemia, septic arthritis and
abscesses. The most common microbial agents were
gram (+) and (-) bacilli and candida. In their study, other
minor infections included urinary tract, vaginal, skin and
mucocutaneous infections.
We detected infection in 22 (16%) of the 115
patients with collagen tissue disease included in this
study. Infection was treated according to the results of
cultures and antibiograms. Two (9%) of the patients with
sepsis died. Tuberculosis infection was not detected in any
of these patients. Shyam et al. (12) followed up 309
patients in their study. They detected infection in one or
more sites in 82 (26.5%) cases. Tuberculosis infection
was often found. In addition, Koh et al. (13) followed
up patients with collagen tissue disease for a period of 4
years. Sixty-seven of them died. Twenty-seven (40.3%)
of them died of infection, 30 (44.8%) died of SLE, and 4
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(5.9%) died of malignancy. These results indicate that
infection plays an important role in the mortality and
morbidity of patients with collagen tissue disease. In
another study supporting this view, Jacobsen et al. (14)
followed up 513 patients with SLE. One hundred twentytwo of them died: 25% of the death rate was infection,
19% was active SLE and 16% end-stage organ failure.
Furthermore, Cerceva et al. (15), in a multicenter study,
followed up 1000 patients with SLE for 5 years. Infection
developed in 27% of them; 5.4% of the 1000 patients
died. Infection was the primary cause of death with a rate
of 28.9%. The infection rates in these studies are close to
those obtained in our cases. We think that the difference
results from the number of patients.
Lee et al. (16) followed up 110 patients with SLE for
4.5 years. In this period, they encountered a 26.3% proportion of infection; 10.1% of them were major infections. Staples et al. (17) followed up 23 patients with SLE
in hospital for 4 weeks and reported a 56.5% proportion
of infections. In a meta-analysis carried out, while infections were detected to be 12.7% of the proportion of
2111 patients administered corticosteroid, this proportion was reported to be 8% in 2087 control cases (4).
Hoffman et al. (5) detected a total of 140 serious infections in 73 of 158 patients with Wegener Granulomatosus who had been administered corticosteroid and
cyclophosphamide. Thirty-nine percent of these infections
were pneumonia. The infection rate was detected to be
16% in patients receiving merely cytotoxic drugs. In
another study, major infection was reported in 2 of 19
patients receiving azathioprine.
Several studies have reported risks of infection ranging from 0 to 20% in methotraxate receivers. The most
frequent opportunistic infections in methotraxate
receivers are P. Carinii pneumonia and Z. Zoster. In one
study, P. Carinii pneumonia was detected in 5 (7%) of 68
patients with Wegener Granulomatosus receiving methotraxate and corticosteroid (6).
These studies, and ours, have demonstrated that
infection is of special significance in collagen tissue diseases. These patients become sensitive to infections
because of being administered corticosteroid and/or
immunosupressive drugs during treatment. Indeed, infection also causes the activation of collagen tissue diseases.
Therefore, we must be careful about the development of
infection during the follow-up period, and must treat
these patients effectively if infection develops.
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